Literature DB >> 17344347

Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.

Penny Salt1, Carly Banner, Sarah Oh, Ly-mee Yu, Susan Lewis, Dingxin Pan, David Griffiths, Berne Ferry, Andrew Pollard.   

Abstract

Children who have siblings and/or who attend day care have higher rates of nasopharyngeal colonization with pneumococci than lone children do. Pneumococcal colonization is usually asymptomatic but is a prerequisite for invasive disease. We studied the effect of social mixing with other children on immunity to a pneumococcal vaccine. One hundred sixty children aged 1 year were immunized with a 7-valent conjugate pneumococcal vaccine. A blood sample was obtained before and 9 to 11 days after the vaccine. The concentration and avidity of antibody against vaccine pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) were studied in relation to pneumococcal carriage rate and measures of social mixing. Children with increased social mixing had higher antibody concentrations against serotypes 4, 9V, 14, and 23F than lone children did. The least-carried serotype, serotype 4, was the one of the most immunogenic. This contrasts with serotype 6B, the most common nasopharyngeal isolate but the least immunogenic. Social mixing in infancy enhances the immune response to a Streptococcus pneumoniae polysaccharide-protein conjugate vaccine at 1 year of age. Exposure to pneumococci in the first year of life may induce immunological priming. An alternative explanation is that differences in immunological experience, such as increased exposure to respiratory viral infections in early childhood, alters the response to vaccines perhaps by affecting the balance between Th1 and Th2 cytokines. The low immunogenicity of serotype 6B polysaccharide might make conditions more favorable for carriage of the 6B organism and explain why 6B pneumococci were more frequently isolated than other serotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344347      PMCID: PMC1865629          DOI: 10.1128/CVI.00344-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

1.  Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses.

Authors:  Françoise Mascart; Virginie Verscheure; Anne Malfroot; Marc Hainaut; Denis Piérard; Stéphane Temerman; Alexandra Peltier; Anne-Sophie Debrie; Jack Levy; Giuseppe Del Giudice; Camille Locht
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

Review 2.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 3.  Immunomodulation and sepsis: impact of the pathogen.

Authors:  Pierre Moine; Edward Abraham
Journal:  Shock       Date:  2004-10       Impact factor: 3.454

4.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.

Authors:  Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-08-25       Impact factor: 5.226

5.  Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae.

Authors:  A Sandgren; K Sjostrom; B Olsson-Liljequist; B Christensson; A Samuelsson; G Kronvall; B Henriques Normark
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

6.  Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study.

Authors:  David Goldblatt; Mahein Hussain; Nick Andrews; Lindsey Ashton; Camilla Virta; Alessia Melegaro; Richard Pebody; Robert George; Anu Soininen; John Edmunds; Nigel Gay; Helena Kayhty; Elizabeth Miller
Journal:  J Infect Dis       Date:  2005-06-23       Impact factor: 5.226

7.  Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life.

Authors:  Christopher C Copenhaver; James E Gern; Zhanhai Li; Peter A Shult; Louis A Rosenthal; Lance D Mikus; Carol J Kirk; Kathy A Roberg; Elizabeth L Anderson; Christopher J Tisler; Douglas F DaSilva; Heidi J Hiemke; Kevin Gentile; Ronald E Gangnon; Robert F Lemanske
Journal:  Am J Respir Crit Care Med       Date:  2004-04-15       Impact factor: 21.405

8.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Risk factors for invasive disease among children in Spain.

Authors:  Inmaculada Pereiró; Javier Díez-Domingo; Leopoldo Segarra; Alfredo Ballester; Amparo Albert; Amparo Morant
Journal:  J Infect       Date:  2004-05       Impact factor: 6.072

10.  Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.

Authors:  Andrew J Pollard; Jan Ochnio; Margaret Ho; Martin Callaghan; Mark Bigham; Simon Dobsong
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  9 in total

1.  Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Authors:  Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

2.  Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Authors:  Shabir A Madhi; Avy Violari; Keith P Klugman; Gina Lin; James A McIntyre; Anne von Gottberg; Patrick Jean-Philippe; Mark F Cotton; Peter Adrian
Journal:  Vaccine       Date:  2011-07-23       Impact factor: 3.641

3.  Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics.

Authors:  Ari J Fried; Michelle L Altrich; Hongye Liu; John F Halsey; Francisco A Bonilla
Journal:  J Clin Immunol       Date:  2013-02-03       Impact factor: 8.317

4.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

5.  Determination of avidity of IgG against protein antigens from Streptococcus pneumoniae: assay development and preliminary application in clinical settings.

Authors:  D C Andrade; I C Borges; N Ekström; T Jartti; T Puhakka; A Barral; H Kayhty; O Ruuskanen; C M Nascimento-Carvalho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-12       Impact factor: 3.267

6.  Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.

Authors:  Adam K A Wright; Daniela M Ferreira; Jenna F Gritzfeld; Angela D Wright; Kathryn Armitage; Kondwani C Jambo; Emily Bate; Sherouk El Batrawy; Andrea Collins; Stephen B Gordon
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

7.  The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.

Authors:  Stefan Flasche; Olivier Le Polain de Waroux; Katherine L O'Brien; W John Edmunds
Journal:  PLoS Comput Biol       Date:  2015-04-16       Impact factor: 4.475

8.  Naturally acquired antibodies against 7 Streptococcus pneumoniae serotypes in Indigenous and non-Indigenous adults.

Authors:  Gabrielle N Gaultier; Eli B Nix; Joelle Thorgrimson; Douglas Boreham; William McCready; Marina Ulanova
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

9.  Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia.

Authors:  N Ms Smith; G A Wasserman; F T Coleman; K L Hilliard; K Yamamoto; E Lipsitz; R Malley; H Dooms; M R Jones; L J Quinton; J P Mizgerd
Journal:  Mucosal Immunol       Date:  2017-05-17       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.